Giuseppe Rosano
Short Professional summary
Giuseppe M.C. Rosano, MD, PhD, is Professor of Cardiology at City St George’s University of London where is is also Director of the MSc in Heart Failure. G.R. is also Director of the Cardiovascular translational laboratory at IRCCS San Raffaele Roma.
G.R. received his medical degree and his specialisation in cardiovascular medicine from “La Sapienza” University of Rome in Rome, Italy, and his PhD in Medical Sciences from the Imperial College of Science and Technology in London, United Kingdom.
G.R. has served as member of the SAG Cardiovascular and of the Cardiovascular Working Party of the European Medicines Agency, he has been board member of the Italian Space Agency and member of the pricing and reimbursement committee at the Italian Drug Agency. G.R. is fellow of the American College of Cardiology, the Japanese Circulation Society and, of the Italian Federation of Cardiology. He has served as board member and President of the Heart Failure Association of the European Society of Cardiology. He serves as Editorial Board Member for European Heart Journal, European Journal of Heart Failure, European Heart Journal—Cardiovascular Pharmacotherapy, ESC Heart Failure, Cardiovascular Diabetology, Nature Research Scientific Reports, Cardiovascular Reviews, Advances in Therapy, European Cardiology Review, and Climacteric.
G.R. has authored or co-authored more than 750 peer-reviewed articles.
My interest in this initiative
I am drawn to the Improving Heart Function initiative for its exceptional educational platform facilitating knowledge exchange on optimal heart failure care practices across specialities. The iHF's integrated approach combining guideline-directed medical therapy with evidence-based interventional strategies aligns perfectly with my comprehensive vision of cardiovascular care. Through this collaborative environment, I value how specialists from different disciplines can enhance their understanding of patient selection criteria for interventional procedures and develop optimal clinical pathways for follow-up care—whether in primary care, in Internal Medicine or Geriatric Medicine wards, in out-patient clinics, catheterisation laboratories, during hospitalisation, or post-discharge. I recognise iHF as a synergistic endeavour where all stakeholders benefit whilst collectively advancing heart failure patient outcomes.
